ストックスクリーナーアプリを入手
435.62
0.84%
3.62
アフターアワーズ：
435.62
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
William Blair Investment Management LLC Has $188.88 Million Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Artisan Partners Limited Partnership Acquires 4,683 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Q4 earnings miss, MASH drug sales drive top line, stock down - MSN
MDGL SEC FilingsMadrigal Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
Fox Run Management L.L.C. Takes $1.06 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra’s Near US$1 Billion Debut Year - Yahoo Finance
Exit Recap: Will Madrigal Pharmaceuticals Inc outperform during market ralliesEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Madrigal: The Easiest Money May Have Been Made (NASDAQ:MDGL) - Seeking Alpha
Director exercises 2,500 Madrigal (MDGL) options at $7.36 - Stock Titan
Madrigal Pharmaceuticals Reports 2025 Financial Results - MyChesCo
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Madrigal to webcast TD Cowen health conference talk Mar. 3 - Stock Titan
Madrigal Grants Inducement Awards to Five Employees - MyChesCo
Madrigal (MDGL) Q4 2025 Earnings Call Transcript - The Globe and Mail
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales - simplywall.st
Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook Reveals 53% Potential Upside In Biotechnology - DirectorsTalk Interviews
Vanguard Group Inc. Sells 65,227 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal’s Rezdiffra Breakthrough Spurs MASH Pipeline Growth And Valuation Debate - Yahoo Finance
MASH Drugs Market to hit US$ 929.05 Million by 2033 | North America - openPR.com
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Bitget
Is now the right time to enter Madrigal Pharmaceuticals Inc.July 2025 Opening Moves & Safe Entry Momentum Tips - mfd.ru
MDGL: B of A Securities Maintains Neutral Rating, Lowers Price T - GuruFocus
Bank of America Issues Pessimistic Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2025 Earnings Call Transcript - Insider Monkey
Fiera Capital Corp Lowers Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus
Madrigal Pharma earnings missed by $1.97, revenue topped estimates - Investing.com Canada
Madrigal Eyes MASH Future As Rezdiffra Nears Blockbuster Revenue - Citeline News & Insights
Earnings call transcript: Madrigal Pharmaceuticals Q4 2025 misses EPS, stock dips - Investing.com India
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highlights: Record Sales and ... By GuruFocus - Investing.com Canada
Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Quarterly Earnings Results, Misses Estimates By $2.61 EPS - MarketBeat
Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales - AlphaStreet News
Madrigal Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) Reports Strong Q4 2025 Performan - GuruFocus
Madrigal Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Earnings Miss - MarketBeat
Madrigal Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Madrigal Pharmaceuticals Stock Drops 11% Despite Reporting Narrower Loss In Q4 - Nasdaq
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday - marketscreener.com
MADRIGAL PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Madrigal Pharmaceuticals (MDGL) Faces Mixed Q4 2025 Results - GuruFocus
Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance Singapore
Madrigal (MDGL) Surpasses Q4 Revenue Expectations, Eyes Future G - GuruFocus
Madrigal down on wider-than-expected Q4 loss (MDGL:NASDAQ) - Seeking Alpha
Madrigal: Q4 Earnings Snapshot - kens5.com
Madrigal Pharma shares fall over 5% as Q4 earnings miss overshadows revenue beat - Investing.com Nigeria
Madrigal Pharma shares fall over 5% as Q4 earnings miss overshadows revenue beat By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results - Bitget
Madrigal Pharmaceuticals Q4 Loss Narrows, Revenue Rises - marketscreener.com
Madrigal: Q4 Financial Results Overview - Bitget
MADRIGAL PHARMACEUTICALS ($MDGL) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q4 Net Loss $2.57 a Share, vs. FactSet Est of $0.90 Loss - marketscreener.com
Madrigal Pharmaceuticals Q4 revenue rises sharply on Rezdiffra sales - TradingView
MDGL: Rezdiffra net sales neared $1B in 2025, with pipeline growth and improved financial position - TradingView
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Skandinaviska Enskilda Banken AB publ - MarketBeat
2.90%
2.73%
大文字化:
|
ボリューム (24 時間):